南财智讯11月14日电，睿智医药在投资者关系活动中表示，公司全资子公司与专业投资机构合作设立投 资基金，通过CVC模式投资前沿创新药项目，赋能产业协同并拓展未来订单。公司正围绕股权激励目 标推进经营工作，力争2025年实现营业收入增长率不低于15%，净利润（剔除股权激励费用）转正。 ...

每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 （记者 王晓波） 2025年1至6月份，睿智医药的营业收入构成为：医药研发服务及生产外包占比99.06%，益生元系列占 比0.52%，租金收入占比0.35%，其他行业占比0.07%。 截至发稿，睿智医药市值为58亿元。 每经AI快讯，睿智医药（SZ 300149，收盘价：11.67元）发布公告称，2025年11月13日，睿智医药接受 国新证券等投资者调研，公司首席财务官（CFO）查胤群等人回答了投资者提出的问题。 ...

Group 1: Equity Incentive Plan - The company announced a restricted stock incentive plan on April 2025, with the first grant date set for July 11, 2025, at a price of 3.05 yuan per share, granting 44.56 million shares to 123 recipients including management and key personnel [2][3] - The equity incentive expenses for the first three quarters of 2025 amounted to 3,563.69 million yuan; excluding these expenses, the net profit attributable to shareholders was 42.72 million yuan, a year-on-year increase of 169.29% [3] Group 2: Employee Retention and Stability - The company's recent employee turnover rate is at a healthy level, indicating good team stability [3] Group 3: Collaboration with Investment Funds - The company has established investment funds in collaboration with professional investment institutions to enhance the innovative drug industry, leveraging their investment capabilities and risk control [3] Group 4: Performance Outlook - The company aims for a revenue growth rate of no less than 15% in 2025, with net profit (excluding equity incentive payment expenses) expected to be positive [3]

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

睿智医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：创新药、抗癌治 癌、AI医药、CRO概念、阿尔茨海默等。 11月14日，睿智医药盘中上涨2.40%，截至10:48，报11.52元/股，成交1.04亿元，换手率1.94%，总市值 57.37亿元。 资金流向方面，主力资金净流入182.84万元，特大单买入378.07万元，占比3.62%，卖出343.06万元，占 比3.29%；大单买入2199.10万元，占比21.06%，卖出2051.27万元，占比19.65%。 睿智医药今年以来股价涨79.44%，近5个交易日涨6.47%，近20日涨2.58%，近60日跌10.70%。 今年以来睿智医药已经2次登上龙虎榜，最近一次登上龙虎榜为7月29日，当日龙虎榜净买入1.65亿元； 买入总计2.56亿元 ，占总成交额比16.71%；卖出总计9095.17万元 ，占总成交额比5.93%。 资料显示，睿智医药科技股份有限公司位于广东省广州市越秀区东风中路268号交易广场28楼，成立日 期2000年1月26日，上市日期2010年12月22日，公司主营业务涉及医药研发与生产外包服务、微生态营 养、微生态医 ...

Core Insights - The Xinjiang Listed Companies Association organized a learning exchange activity in Shanghai for 27 listed companies and related institutions, focusing on "benchmarking advanced practices and empowering enhancement" [1][2] - The event included training on regulatory policies from the Shanghai Stock Exchange, emphasizing compliance in daily operations, information disclosure, and capital operations [1] - Participants visited four benchmark companies in Shanghai to learn about their advanced experiences in technology innovation, industry operations, corporate governance, and ESG practices [2] Group 1 - The activity aimed to build an efficient learning and cooperation bridge for Xinjiang listed companies [1] - The training provided insights into compliance management and risk prevention, highlighting common issues in information disclosure and regulatory processes [1] - The event facilitated a platform for collaboration between Xinjiang enterprises and Shanghai resources, enhancing awareness of collaborative benchmarking [2] Group 2 - The association plans to continue organizing various learning exchange activities to meet enterprise development needs and promote healthy development in the Xinjiang capital market [2] - The initiative aims to deepen understanding of industrial upgrades, technological innovation, and capital operations [2] - The event strengthened the foundation for high-quality development of Xinjiang listed companies through enhanced capabilities and resource integration [2]

Group 1 - Xinpeng Co., Ltd. provided a guarantee of 50 million yuan for its wholly-owned subsidiary, increasing the total guarantee amount to 1.258 billion yuan, which is 115.47% of the latest audited net assets [1] - Yonggui Electric's subsidiary signed a contract worth 15.8652 million yuan with CRRC Zhuzhou for supplying components for the Wuhan rail transit project [1] - Huada Technology secured project designations from multiple domestic automakers and battery companies, with a total expected sales amount of 2.9 billion yuan, over 80% of which is related to new energy projects [2] Group 2 - China National Machinery International signed a contract for a 5.71 billion yuan hospital construction project in Iraq, which represents 4.68% of the company's expected revenue for 2024 [3] - Fangzhi Technology plans to acquire 100% of Zhixiang Technology for 116 million yuan, focusing on AI-driven smart learning and sports solutions [4] - Demingli is in the early stages of planning a refinancing initiative, with no specific details on the amount or method yet [5] Group 3 - Hesheng Silicon Industry announced a shareholder's plan to reduce holdings by up to 2.29%, equating to 27.0706 million shares [7] - ST Lanhua's subsidiary plans to invest up to 65 million yuan in a juice beverage project in Chongqing [8] - Ruizhi Pharmaceutical developed an automated synthesis system for antibody-drug conjugates and nucleoside monomers in collaboration with East China Normal University [9] Group 4 - Lianying Laser's controlling shareholder intends to reduce holdings by up to 3 million shares, representing 0.88% of the total share capital [10] - Songyuan Safety's controlling shareholder plans to reduce holdings by up to 1% of the total share capital [12] - ST Kaixin's actual controller and major shareholders plan to transfer 5% of the company's shares at a price of 27.85 yuan per share [13] Group 5 - Bojun Technology plans to invest approximately 1 billion yuan in a new automotive parts production base, aiming for an annual capacity of 24 million sets [13] - Litong Electronics' controlling shareholder committed to not reducing holdings for 24 months, while other shareholders plan to reduce a total of 3.03% of shares [14] - Yaoyigou's actual controller intends to transfer 5.23% of shares to a company director at a price of 24 yuan per share [15] Group 6 - Baiwei Storage submitted H-share listing application materials to the China Securities Regulatory Commission [18] - Jinshi Yaya obtained a drug registration certificate for glucosamine sulfate capsules, which are suitable for osteoarthritis treatment [19] - Shangtai Technology plans to invest approximately 4.07 billion yuan in a lithium-ion battery anode material project [19] Group 7 - Xinlitai's shareholder plans to reduce holdings by up to 800,000 shares, representing 0.07% of the total share capital [20] - Yunnan Baiyao elected Zhang Wenxue as the chairman of the board for a three-year term [21] - Huading Co., Ltd. announced that two shareholders plan to reduce their holdings by up to 3% of the total share capital [23] Group 8 - Jiahua Technology's shareholder plans to reduce holdings by up to 0.65% of the total share capital [25]

Core Viewpoint - The company has successfully developed an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers in collaboration with East China Normal University, which enhances R&D efficiency and service quality [1] Group 1 - The full subsidiary of the company, Shanghai Ruizhi Pharmaceutical Research Group Co., Ltd., has partnered with East China Normal University to develop the new synthesis system [1] - The new system allows for seamless transition from laboratory research to industrial production, indicating a significant advancement in the production process [1] - The implementation of this system is expected to significantly shorten the R&D cycle and improve overall research efficiency [1]

格隆汇11月10日丨睿智医药(300149.SZ)公布，基于《战略合作框架协议》的合作背景，公司全资子公 司上海睿智医药研究集团有限公司与华东师大共同组建了前沿技术联合实验室，在药物发现、生物芯 片、药物递送系统、药物偶联物（XDC）等领域开展合作研究。近期，双方成功联合自主研发了抗体 偶联药物（ADC）与核苷酸单体自动化、智能化、集成化桌面式合成系统，可以实现从实验室研发到 产业生产的无缝衔接与范式重构。其中ADC微流智造系统可以融合超快激光微流芯片与智能过程控 制，推动抗体药物偶联从"间歇式操作"向"平台化智造"升级，推动ADC工艺向精准可控与高效迭代的方 向发展；核苷酸单体微流合成系统可以依托无催化剂、无碱参与的"智能微流"路径，实现亚磷酰胺单体 的连续、稳定、绿色合成，为核酸药物原料构建自主、安全、高效的供应新标准。ADC与核苷酸单体 自动化、智能化、集成化桌面式合成系统的运用，可以显著缩短研发周期，提升研发效率，助力公司为 客户提供更优质的服务。 ...

Core Viewpoint - The company has established a cutting-edge technology joint laboratory with East China Normal University to enhance research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDC) [1] Group 1: Collaboration and Research Development - The collaboration is based on a strategic cooperation framework agreement, aiming to advance research in various pharmaceutical fields [1] - The joint efforts have led to the successful development of an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from "batch operation" to "platform-based intelligent manufacturing" [1] - The nucleotide monomer microfluidic synthesis system utilizes a "smart microfluidic" approach without catalysts or alkali participation, enabling continuous, stable, and green synthesis of phosphoramidite monomers [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency [1] - This advancement will allow the company to provide higher quality services to its clients [1]